These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34323681)

  • 1. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
    Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
    Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
    Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
    Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
    Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
    Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
    Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
    Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
    Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
    Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
    Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
    Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
    Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
    Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
    Takehara K; Ihn H; Sato S
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.